Published in Vasc Med on January 01, 2001
Inflammation, Infection, and Future Cardiovascular Risk | NCT00005496
Mannan binding lectin as an adjunct to risk assessment for myocardial infarction in individuals with enhanced risk. J Exp Med (2004) 1.30
Association of cystatin C with adverse outcomes. Curr Opin Nephrol Hypertens (2009) 1.11
Cystatin C, kidney function and cardiovascular disease. Pediatr Nephrol (2006) 0.98
Genetic and other factors determining mannose-binding lectin levels in American Indians: the Strong Heart Study. BMC Med Genet (2009) 0.82
β2-microglobulin, cystatin C, and creatinine and risk of symptomatic peripheral artery disease. J Am Heart Assoc (2014) 0.77
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med (2000) 18.04
C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA (2001) 15.85
Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med (1996) 8.57
Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation (2000) 8.17
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med (2001) 7.51
Association between dietary patterns and plasma biomarkers of obesity and cardiovascular disease risk. Am J Clin Nutr (2001) 5.67
Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA (2001) 5.54
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1999) 3.90
Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation (2000) 3.66
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1998) 3.19
Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem (2001) 3.17
Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem (2001) 3.12
Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation (2000) 2.94
Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem (2001) 2.81
Novel clinical markers of vascular wall inflammation. Circ Res (2001) 2.80
Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med (2002) 2.70
Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem (2001) 2.67
The primary prevention of myocardial infarction. N Engl J Med (1992) 2.63
Blood pressure and inflammation in apparently healthy men. Hypertension (2001) 2.55
Effect of marathon running on inflammatory and hemostatic markers. Am J Cardiol (2001) 2.50
Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem (1999) 2.35
Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation (1997) 2.34
Discordance between meta-analyses and large-scale randomized, controlled trials. Examples from the management of acute myocardial infarction. Ann Intern Med (1995) 2.31
Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest (1996) 2.31
The pravastatin inflammation CRP evaluation (PRINCE): rationale and design. Am Heart J (2001) 2.12
Periodontal disease and risk of subsequent cardiovascular disease in U.S. male physicians. J Am Coll Cardiol (2001) 2.11
High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem (2001) 2.06
Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest (1999) 2.03
HbA1c measured in stored erythrocytes and mortality rate among middle-aged and older women. Diabetologia (2007) 2.03
Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem (2001) 2.01
Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet (2005) 2.00
Large-scale trials of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3, and GUSTO-1. Ann Intern Med (1993) 1.97
Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation (1999) 1.96
C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol (1998) 1.96
Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med (1992) 1.92
The association of serum lipids and inflammatory biomarkers with renal function in men with type II diabetes mellitus. Kidney Int (2006) 1.84
Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study. Diabetologia (2007) 1.80
Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem (2000) 1.74
Soluble P-selectin and the risk of future cardiovascular events. Circulation (2001) 1.69
Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. J Am Coll Cardiol (1993) 1.68
Novel inflammatory markers of coronary risk: theory versus practice. Circulation (1999) 1.65
False increase of cardiac troponin I with heterophilic antibodies. Clin Chem (1998) 1.63
Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. Diabetes Care (2001) 1.63
D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost (2006) 1.62
Height and incidence of cardiovascular disease in male physicians. Circulation (1993) 1.62
Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening. J Am Coll Cardiol (2000) 1.62
Multi-locus candidate gene polymorphisms and risk of myocardial infarction: a population-based, prospective genetic analysis. J Thromb Haemost (2006) 1.61
Late onset of renal and hepatic cysts in Pkd1-targeted heterozygotes. Nat Genet (1999) 1.61
Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: a Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy. Clin Chem (2000) 1.58
Prospective evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of stroke. Circulation (1999) 1.57
Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol (1999) 1.54
Soluble CD40L and cardiovascular risk in women. Circulation (2001) 1.52
Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem (2000) 1.52
Surgical management of carcinoid heart disease. Ann Thorac Surg (1991) 1.50
Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation (2001) 1.50
Inflammation, the acute phase response and atherosclerosis. Clin Chem Lab Med (1999) 1.47
C-reactive protein gene polymorphisms and the risk of venous thromboembolism: a haplotype-based analysis. J Thromb Haemost (2004) 1.46
Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J (2002) 1.45
A prospective evaluation of the interleukin-1 receptor antagonist intron 2 gene polymorphism and the risk of myocardial infarction. Thromb Haemost (2001) 1.45
Qualitative and quantitative effects of APOE genetic variation on plasma C-reactive protein, LDL-cholesterol, and apoE protein. Genes Immun (2006) 1.44
Mutation in the promoter region of the beta-fibrinogen gene and the risk of future myocardial infarction, stroke and venous thrombosis. Eur Heart J (2001) 1.44
Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults. Am J Cardiol (2001) 1.44
A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women. Rationale, design, and methods. The WACS Research Group. Ann Epidemiol (1995) 1.44
Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem (1998) 1.43
Should survivors of myocardial infarction with low ejection fraction be routinely referred to arrhythmia specialists? JAMA (1996) 1.39
Evaluation of the APEC analyzer for whole blood glucose. Testing in a pediatric setting. Am J Clin Pathol (1995) 1.39
Factor V Leiden and recurrent venous thromboembolism. Thromb Haemost (1996) 1.39
A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol (2001) 1.38
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.35
Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med (2000) 1.33
Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol (1998) 1.32
Truncal adiposity, relative growth hormone deficiency, and cardiovascular risk. J Clin Endocrinol Metab (2004) 1.31
Inflammation, infection, and cardiovascular risk: how good is the clinical evidence? Circulation (1998) 1.31
Genetic variation in alcohol dehydrogenase and the beneficial effect of moderate alcohol consumption on myocardial infarction. N Engl J Med (2001) 1.30
Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians. Am J Med (1990) 1.25
Lipid levels and the risk of ischemic stroke in women. Neurology (2007) 1.23
Differential leucocyte count and the risk of future coronary artery disease in healthy men and women: the EPIC-Norfolk Prospective Population Study. J Intern Med (2007) 1.22
Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol (1999) 1.22
Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost (2009) 1.22
Migraine and biomarkers of cardiovascular disease in women. Cephalalgia (2007) 1.21
Oral administration of clotrimazole and blockade of human erythrocyte Ca(++)-activated K+ channel: the imidazole ring is not required for inhibitory activity. J Pharmacol Exp Ther (1995) 1.17
Influence of genetic variation in the C-reactive protein gene on the inflammatory response during and after acute coronary ischemia. Ann Hum Genet (2006) 1.14
Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med (1997) 1.13
Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment: Writing Group I. Circulation (2000) 1.13
Effect of vitamin supplementation to HIV-infected pregnant women on the micronutrient status of their infants. Eur J Clin Nutr (2005) 1.12
Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians. Circulation (1997) 1.11
Beta 2-microglobulin and neopterin: predictive markers for human immunodeficiency virus type 1 infection in children? J Clin Microbiol (1990) 1.11
Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis (2001) 1.11
Glycosylated hemoglobin and risk of colorectal cancer and adenoma (United States). Cancer Causes Control (1999) 1.08
Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation (1997) 1.08